OCD Treatment in Los Angeles, CA
Introducing the First FDA-Cleared Non-invasive Medical Device for the Treatment of OCD
As of September 2018, our medical partner BrainsWay, announced that Deep TMS (dTMS) Treatment was approved by the FDA for treatment of Obsessive Compulsive Disorder (OCD). Our non-invasive treatment utilizing the TMS device provided by BrainsWay is a painless and comfortable treatment that can help relieve multiple & common symptoms that numerous people live with on a daily basis, including OCD.
Recently, TMS has been helping change the lives of OCD patients. Our TMS treatment plan offers a clinically-proven solution to treat obsessive-compulsive disorder. The treatment performs magnetic stimulation of frontal brain structures and networks, targeting previously unreachable areas of the brain with its proprietary H7-coil, allowing it to effectively treat OCD. TMS has many advantages over other treatment options, as it is an outpatient procedure that is generally well tolerated and entails minimal side effects.
In many cases, we find that TMS patients experience relief and positive results soon after the first treatment. We have appointments available now and offer FREE consultations to all new patients that inquire.
Common Themes related to Obsessive Compulsive Disorder
- Fear of contamination or dirt
- The consistent need for symmetry, sequences, and order
- Hostile, aggressive and terrible thoughts about harming oneself or others
- Inability to control undesirable thoughts related to physical violence, sex or religion
Do you or a loved one experience some or any of these symptoms? You may be a candidate, Contact Us today!
BrainsWay conducted the only multi-center trial for obsessive-compulsive disorder patients over the course of 6 weeks on numerous subjects utilizing a double-blind study.
The multi-center study demonstrated that after six weeks of treatment, there was a statistically significant improvement in the primary endpoint results for the active treatment group. The improvement was also maintained one month after t10 weeks of treatment. The primary outcome measure of this study was the OCD Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the gold standard measure of OCD symptoms severity. Importantly, 38.1% of patients in the active group achieved a response of more than 30% reduction in symptoms severity as measured by Y-BOCS.
See the official FDA press release here!